Company profile
Imagion Biosystems Limited
OTC: IBXXF · Healthcare · Medical - Diagnostics & Research
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 33
v0.1 · 5/100 weight · pillars only
↑ Piotroski F, market scale · ↓ Altman-Z, listing tenure
Methodology →Revenue TTM
—
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
—
Employees
11
as of 2026-08-23
Market cap
$6.5M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue—0 AUD2025
Net income—-4.3M AUD2025
Operating income—-3.6M AUD2025
Total assets—2.0M AUD2025
Liabilities—4.2M AUD2025
Equity—-2.2M AUD2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Imagion Biosystems Limited’s financial profile?
Imagion Biosystems Limited has no structured financials on file — private or non-XBRL filer.
Peers · Healthcare
Liminatus Pharma, Inc. Class A Common Stock——Curative Biotechnology, Inc.——Curanex Pharmaceuticals Inc Common Stock——Acurx Pharmaceuticals, Inc.——Cardiac Biotech Solutions Inc.——Kairos Pharma, Ltd.——Neighbors
San Diego →Key facts
CEORobert Romeo Proulx
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersSan Diego, CA
ExchangeOTC: IBXXF
Employees11
IPO date2020-09-21
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.